Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes ...

Documents dated Aug. 6 also include multiple renderings of the campus, which would include 12 data center buildings, three ...

Construction activity surged in June with total starts reaching $1.33 trillion at a seasonally adjusted annual rate, driven ...

From geopolitics to climate, tech to social change, News18 World live blog delivers real-time updates on what is the latest ...

Poquoson’s Anabelle Simmons and Jeff Imgrund were named as the VHSL Class 2 all-state girls soccer Player of the Year and ...

Hamilton County has finalized the $4.2 million purchase of Sheridan Airport, aiming to accommodate rising demand for private ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...

The amount of credits the company receives is contingent upon its meeting job creation and capital investment goals.

Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.